Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Carglumic Acid (Ureidoglutaric acid) is an orphan drug used to treat hyperammonemia in patients with N-acetyl glutamate synthase absence. This rare hereditary disease results in elevated blood levels of ammonia, which can eventually cross the blood-brain barrier and lead to neurologic problems, coma, cerebral edema, and death. Carglumic acid was approved by the U.S. FDA on 18 March 2010.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
200 mg | 在庫あり | ¥ 11,000 | |||
500 mg | 在庫あり | ¥ 20,500 | |||
1 g | 在庫あり | ¥ 27,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 13,000 |
説明 | Carglumic Acid (Ureidoglutaric acid) is an orphan drug used to treat hyperammonemia in patients with N-acetyl glutamate synthase absence. This rare hereditary disease results in elevated blood levels of ammonia, which can eventually cross the blood-brain barrier and lead to neurologic problems, coma, cerebral edema, and death. Carglumic acid was approved by the U.S. FDA on 18 March 2010. |
別名 | Carbaglu, N-Carbamylglutamate, N-Carbamyl-L-glutamic acid, Carbamylglutamic acid, Carbamino-L-glutamic acid, Ureidoglutaric acid |
分子量 | 190.15 |
分子式 | C6H10N2O5 |
CAS No. | 1188-38-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (236.66 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Carglumic Acid 1188-38-1 Others Carbaglu N-Carbamylglutamate N-Carbamyl-L-glutamic acid inhibit Carbamylglutamic acid Inhibitor Carbamino-L-glutamic acid Ureidoglutaric acid inhibitor